pharmadog
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

456 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT787Endpoints593BioPharma Dive228onclive165Fierce Biotech64BioSpace63raps25
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology6
  • <![CDATA[Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026]]>
    <![CDATA[Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[EGFR-Targeted Therapy Sequencing After Resistance in NSCLC]]>
    <![CDATA[Learn how clinicians tackle EGFR lung cancer resistance—using NGS, radiation, chemo, amivantamab, and ADCs to tailor next-line therapy.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[HERIZON-GEA-01 Study Design, Geographic Distribution, and PD-L1 Testing Considerations]]>
    <![CDATA[Experts debate PD‑L1 testing in HER2+ metastatic gastric cancer as new trial data reshapes when to add immunotherapy.]]>
    onclive
← prev
page 16 of 19
next →
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
· 2mo ago
↗ source
  • <![CDATA[Integrating Evidence and Identifying Future Research Needs in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]>
    <![CDATA[Experts debate real-world evidence for prostate cancer drug comparisons, weighing trial limits, bias, and data that guides care.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Approaching First-Line Treatment in PD-L1 CPS <1 HER2-Positive GEA]]>
    <![CDATA[Zanidatamab’s dual HER2 binding shows striking single-agent activity in gastric and biliary cancers, hinting at synergy beyond pertuzumab-trastuzumab blockade.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Co-Occurring Mutations in NSCLC: Influence on Prognosis and Immunotherapy Response]]>
    <![CDATA[Learn how STK11 and MTAP loss reshape NSCLC prognosis, immunotherapy response, and open doors to dual-checkpoint and PRMT5 inhibitor trials.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Evaluating Observational and Propensity Matched Studies in Metastatic Castration Sensitive Prostate Cancer (mCSPC)]]>
    <![CDATA[Experts weigh real‑world evidence for prostate cancer drug comparisons, explaining bias risks, data quality, and how it complements trials.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Reigniting Your Curiosity During Fellowship ]]>
    <![CDATA[Megan M. Dupuis, MD, PhD, discusses how oncology fellows can keep their personal and professional curiosities alive during fellowship.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[MANEUVER Trial Underscores Potential Paradigm Shift Toward Targeted Approaches in TGCT ]]>
    <![CDATA[R. Lor Randall, MD, FACS, discusses how the introduction of systemic therapies like pimicotinib in TGCT enables a tumor biology–informed approach to care.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr McGregor on the DAD-IO Trial of Sacituzumab Govitecan and EV in Metastatic Urothelial Carcinoma]]>
    <![CDATA[Bradley McGregor, MD, discusses the background and design of the phase 1/2 DAD-IO trial in metastatic urothelial carcinoma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer]]>
    <![CDATA[Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC]]>
    <![CDATA[Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Chari on Frontline Combinations and Transplant Approaches in Multiple Myeloma]]>
    <![CDATA[Ajai Chari, MD, discusses frontline treatment and transplant considerations in multiple myeloma.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[FDA Accepts sNDA for Taletrectinib in ROS1+ NSCLC]]>
    <![CDATA[An sNDA with updated data for taletrectinib was accepted by the FDA for TKI-naive and pretreated advanced ROS1+ NSCLC]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Cancer]]>
    <![CDATA[]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Herrera on the Significance of the FDA Approval of Nivolumab Plus AVD for Classical Hodgkin Lymphoma]]>
    <![CDATA[Alex Herrera, MD, discusses the FDA approval of nivolumab plus AVD for classical Hodgkin lymphoma and its impact on clinical practice.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Dr Sznol on Biomarkers of Response in Metastatic Melanoma]]>
    <![CDATA[Mario Sznol, MD, discusses the uncertainties around predicting benefit with immune checkpoint inhibitors in metastatic melanoma. ]]>
    onclive · 2mo ago↗ source
  • Bayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
    <figure><div><img src="https://imgproxy.divecdn.com/gRkyNZ1AbgGTL_5MqeKhbG0YuhnzTHcUYxQb5ULTKUc/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0yMjA4MzAxNTQ0LmpwZ…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[Transformational Utah Investment in Artificial Intelligence and Computing to Advance Health and Discovery]]>
    <![CDATA[The State of Utah has made a visionary investment in AI and advanced computing infrastructure to advance research.]]>
    onclive · 2mo ago↗ source
  • Novo hikes guidance on Wegovy pill’s fast sales start
    <p>In its latest earnings report, the Danish drugmaker said sales and profit should shrink less than the company originally anticipated thanks to strong prescription numbers for its new obesity pil…
    BioPharma Dive · 2mo ago↗ source
  • Avalo shares spike on skin drug data; BioNTech to cut staff
    <figure><div><img src="https://imgproxy.divecdn.com/idsdMAHsPbXObDUtQW2qRG7uveBUVv6HCTn9NTtlDOI/g:nowe:0:0/c:1207:682/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0x…
    BioPharma Dive · 2mo ago↗ source
  • <![CDATA[ASCO 2026 HR+ and HER2+ Breast Cancer Preview: Read up on the Insights to Know Before You Go]]>
    <![CDATA[Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting. ]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Consensus Viewpoints Offer Guidance in Rapidly Evolving Multiple Myeloma Management]]>
    <![CDATA[Ajai Chari, MD, outlines key consensus viewpoints and recommendations for multiple myeloma management from Bridging the Gaps 2025.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Comparing Approved Checkpoint Inhibitor Regimens and Optimal Treatment Duration]]>
    <![CDATA[New SGO 2026 data shows frontline checkpoint inhibitors deliver 4-year survival gains and near-zero relapse after two years in DMMR cancers.]]>
    onclive · 2mo ago↗ source
  • <![CDATA[Disease Assessment and Mutational Testing in Progressive CLL]]>
    <![CDATA[Experts discuss relapsed CLL workup, using PET-CT and lymph node biopsy to rule out Richter’s, plus resistance testing to guide next therapy.]]>
    onclive · 2mo ago↗ source